Vlado Perkovic's Publications

• Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis

  Journal articles

  2020

  Journal of the American Society of Nephrology

• Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial

  Journal articles

  2020

  Journal of the American Society of Nephrology

• SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS

  Journal articles

  2020

  Kidney International Reports

• SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA A SYSTEMATIC REVIEW AND ANALYSIS

  Journal articles

  2020

  Kidney International Reports

• THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

  Journal articles

  2020

  Journal of the American College of Cardiology

• SUN-161 CIRCULATING AUTOANTIBODIES TOERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES

  Journal articles

  2020

  Kidney International Reports

• Varying association of extended hours dialysis with quality of life

  Journal articles

  2019

  Clinical Journal of the American Society of Nephrology

• The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

  Journal articles

  2019

  The Lancet Rheumatology

• Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial

  Conference Papers

  2019

  DIABETES-METABOLISM RESEARCH AND REVIEWS

• Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c 7%: Results From the CREDENCE Trial

  Conference Papers

  2019

  CIRCULATION

• Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review

  Journal articles

  2019

  BMJ Global Health

• SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

  Journal articles

  2019

  The Lancet Diabetes and Endocrinology

• The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

  Journal articles

  2019

  Diabetologia

• Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering

  Journal articles

  2019

  CMAJ

• Blood pressure: at what level is treatment worthwhile? (vol 42, pg 127, 2019)

  Journal articles

  2019

  AUSTRALIAN PRESCRIBER

• P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

  Journal articles

  2019

  European Heart Journal

• Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

  Journal articles

  2019

  Diabetologia

• Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis

  Journal articles

  2019

  JAMA Internal Medicine

• Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial

  Journal articles

  2019

  Nephrology

• Estimated GFR (eGFR) loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER

  Conference Abstracts

  2019

  DIABETOLOGIA

• An exploration of factors mediating the effects of canagliflozin on heart failure in patients with type 2 diabetes

  Conference Abstracts

  2019

  DIABETOLOGIA

• Canagliflozin in patients with type 2 diabetes and macroalbuminuria: data from the CANVAS program

  Conference Abstracts

  2019

  DIABETOLOGIA